Pathogenesis and management of sodium and water retention in cardiac failure and cirrhosis

Seminars in Nephrology

Volumn 21, Issue 2, 2001, Pages 157-172

  Schrier, Robert W ^a   Gurevich, Andrey K ^a   Cadnapaphornchai, Melissa A ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; AQUAPORIN 1; AQUAPORIN 2; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRAIN NATRIURETIC PEPTIDE; CARBON TETRACHLORIDE; CARVEDILOL; CHLORIDE ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FUROSEMIDE; METOPROLOL; MINERALOCORTICOID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NORADRENALIN; PROSTACYCLIN; PROSTAGLANDIN E2; RAMIPRIL; RENIN; SODIUM ION; SPIRONOLACTONE; UNINDEXED DRUG; VASOPRESSIN;

CARDIOVASCULAR AUTOREGULATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG EFFICACY; EDEMA; FLUID BALANCE; HEMODYNAMICS; HORMONAL REGULATION; HUMAN; LIVER CIRRHOSIS; NATRIURESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SODIUM RETENTION; VASOPRESSIN RELEASE; WATER DEPRIVATION; WATER RETENTION;

EID: 0035079769     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1053/snep.2001.20933     Document Type: Review

References (169)

1. Fluids of body
2. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1)
3. Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2)
4. Recovery from 'hepatorenal syndrome' after orthotopic liver transplantation
5. Transplantation of cadaveric kidneys from patients with hepatorenal syndrome - Evidence for the functional nature of renal failure in advanced liver disease
6. The role of the kidney in Laennec's cirrhosis of the liver
7. The problem of cardiac edema
8. Hemodynamics, compartments and the renin-aldosterone system in chronic heart failure
9. Effective plasma volume in cirrhosis with ascites. Evidence that a decreased value does not account for renal sodium retention, a spontaneous reduction in glomerular filtration rate (GFR), and a fall in GFR during drug-induced diuresis
10. The role of sodium in the production of edema
11. Ascites and its delivery
12. Three types of 'natural' diuresis
13. Cardiac abnormalities in liver cirrhosis
14. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis
15. Pregnancy: An overfill or underfill state
16. Plasma renin in chronic experimental heart failure and during renal sodium "escape" from mineralocorticoids
17. Assessment of the renin-angiotensin system in cirrhotic patients. Comparison between plasma renin activity and direct measurement of immunoreactive renin
18. The effect of prolonged intravenous infusion of aldosterone in a normal human subject
19. Mineralocorticoid escape in patients with compensated cirrhosis and portal hypertension
20. Pathogenesis of ascites formation: Mechanism of impaired aldosterone escape in cirrhosis
21. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats
22. Plasma levels of immunoreactive atrial natriuretic factor in healthy subjects and in patients with edema
23. Atrial natriuretic factor in normal subjects and heart failure patients - Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion
24. Atrial natriuretic factor in cirrhosis with ascites: Plasma levels, cardiac release and splanchnic extraction
25. Plasma human atrial natriuretic factor in cirrhosis and ascites with and without functional renal failure
26. Variability of atrial natriuretic peptide plasma levels in ascitic cirrhotics: Pathophysiological and clinical implications
27. Physiology of ADH secretion
28. The osmoregulation of vasopressin
29. Peripheral arterial vasodilation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis
30. Body fluid volume regulation in health and disease: A unifying hypothesis
31. Peripheral arterial vasodilation in cirrhosis and impaired mineralocorticoid escape
32. A unifying hypothesis of body fluid volume regulation. The Lilly Lecture 1992
33. Paradoxes of body fluid volume regulation in health and disease. A unifying hypothesis
34. Pathophysiology of renal fluid retention
35. Mechanism of suppression of vasopressin during alpha-adrenergic stimulation with norepinephrine
36. Mechanism of effect of thoracic inferior vena cava constriction on renal water excretion
37. Mechanism of stimulation of vasopressin release during beta adrenergic stimulation with isoproterenol
38. Role of plasma vasopressin in impaired water excretion of glucocorticoid deficiency
39. Mechanisms of portal hypertension-induced alterations in renal hemodynamics, renal water excretion, and renin secretion
40. Mechanism of effect of nicotine on renal water excretion
41. Effect of arginine vasopressin antagonist on renal water excretion in glucocorticoid and mineralocorticoid deficient rats
42. Trends in hospitalization for heart failure in the United States, 1973-1986: Evidence for increasing population prevalence
43. Aldosterone in congestive heart failure: Analysis of determinants and role in sodium retention
44. The role of renin and aldosterone in the salt retention of edema
45. Escape from the sodium-retaining effects of mineralocorticoids: Role of ANF and intrarenal hormone systems
46. The renin-angiotensin-aldosterone system in congestive failure in conscious dogs
47. Role of endogenous atrial natriuretic factor in acute congestive heart failure
48. Renal interaction between sympathetic activity and ANP in rats with chronic ischemic heart failure
49. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure
50. Hormones and hemodynamics in heart failure
51. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
52. Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators
53. Neurohormonal receptors in the failing heart
54. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts
55. Induction of cardiac fibrosis by aldosterone
56. Effects of atrial natriuretic peptide on renal arterioles: Morphometric analysis using microvascular casts
57. Acute oliguric renal failure induced by indomethacin: Possible mechanism
58. Pharmacological modulation of secondary mediator systems - Cyclic AMP and cyclic GMP - On inflammatory hyperalgesia
59. Radioimmunoassay of plasma arginine vasopressin in hyponatremic patients with congestive heart failure
60. Clinical settings and vasopressin function in hyponatraemic children
61. Arginine vasopressin gene expression in chronic cardiac failure in rats
62. Effects of chronic administration of a vasopressin antagonist with combined antivasopressor and antiantidiuretic activities in rats with left ventricular dysfunction
63. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist
64. Upregulation of aquaporin-2 water channel expression in chronic heart failure rat
65. Congestive heart failure in rats is associated with increased expression and targeting of aquaporin-2 water channel in collecting duct
66. Modulation of plasma and platelet vasopressin by cardiac function in patients with heart failure
67. Selective V2-receptor vasopressin antagonism decreases urinary aquaporin-2 excretion in patients with chronic heart failure
68. Identification of hyponatremia as a risk factor for the development of functional renal insufficiency during converting enzyme inhibition in severe chronic heart failure
69. The treatment of Heart Failure: Guidelines
70. Guidelines for the evaluation and manegement of the heart failure. Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines
71. Effects of enalapril on mortality in severe congestive heart failure
72. Effect of enalapril on survival in patients with reduced left-ventricular ejection fractions and congestive heart failure
73. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
74. Therapy of heart failure
75. The physiologic basis of diuretic synergism: Its role in treating diuretic resistance
76. Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention
77. The effect of digoxin on mortality and morbidity in patients with heart failure
78. The effect of carvedilol on mortality and morbidity in patients with chronic heart failure
79. Carvedilol produces dose related improvements in left ventricular function and survival in subjects with chronic heart failure
80. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure
81. Metoprolol in patients with mild to moderate heart failure: Effects on ventricular function and cardiopulmonary exercise testing
82. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: The Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF)
83. A randomised trial
84. Prognostic significance of transient ischemic episodes: Response to treatment shows improved prognosis. Results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up
85. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction
86. The effect of carvedilol on contrast echocardiography in comparison to metoprolol in conscious dogs
87. Long-term effects of carvedilol in idiopathic dilated cardiomyopathy with persistent left ventricular dysfunction despite chronic metoprolol. The Heart-Muscle Disease Study Group
88. Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure
89. Alpha-blockers and congestive heart failure: Early termination of an arm of the ALLHAT trial
90. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
91. The aldosterone antagonist spironolactone prolongs the survival of chronic heart failure patients. The results of the RALES study. The Randomized Aldactone Evaluation Study
92. Study of the month. The RALES study (randomized aldactone evaluation study)
93. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators
94. Inverse relationship between aldosterone and large artery compliance in chronically treated heart failure patients
95. Chronic administration of aldosterone depresses baroreceptor reflex function in the dog
96. Calcium channel blockers in cardiac failure
97. Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group
98. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group
99. Hemodynamic and electrophysiologic effects of first- and second-generation calcium antagonists
100. Haemodynamic and radionuclide effects of amlodipine in coronary artery disease
101. Pre- and afterload reduction in chronic mitral regurgitation: A double-blind randomized placebo-controlled trial of the acute and 2 weeks' effect of nifedipine or isosorbide dinitrate treatment on left ventricular function and the severity of mitral regurgitation
102. Afterload reduction: A comparison of captopril and nifedipine in dilated cardiomyopathy
103. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group
104. Xamoterol in severe heart failure
105. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group
106. A dosedependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators
107. Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure. Second Prospective Randomised Study of Ibopamine on Mortality and Efficacy (PRIME II) Investigators
108. Piroximone, dobutamine and nitroprusside: Comparative effects on haemodynamics in patients with congestive heart failure
109. Effects of dobutamine and/or nitroprusside on the pulmonary circulation in patients with pulmonary hypertension secondary to end-stage heart failure
110. Splanchnic venous pressure-volume relation during experimental acute ischemic heart failure. Differential effects of hydralazine, enalaprilat, and nitroglycerin
111. Experimental studies of the load reducing effects of nitroglycerin in heart failure
112. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study
113. Concurrent hydralazine administration prevents nitroglycerin-induced hemodynamic tolerance in experimental heart failure
114. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group
115. Augmentation of coronary blood flow with intra-aortic balloon pump counter-pulsation
116. Intra-aortic balloon counterpulsation before primary percutaneous transluminal coronary angioplasty reduces catheterization laboratory events in high-risk patients with acute myocardial infarction
117. Successful treatment of severe myocardial failure after postpartum haemorrhage with the use of an intra-aortic balloon pump
118. Maximizing management of patients with decompensated heart failure
119. Heart booster: A pericardial support device
120. The AB-180 circulatory support system: Summary of development and plans for phase I clinical trial
121. Permanent ventricular assist device support versus cardiac transplantation
122. Temporal relationship between the decrease in arterial pressure and sodium retention in conscious spontaneously hypertensive rats with carbon tetrachloride-induced cirrhosis
123. Vasodilatation and sodium retention in prehepatic portal hypertension
124. The relationship of plasma volume, portal hypertension, ascites, and renal sodium and water retention in cirrhosis: The "overflow" theory of ascites formation
125. Sodium retention in dogs with cirrhosis and ascites: Efferent mechanisms
126. Sodium retention and ascites formation in dogs with experimental portal cirrhosis
127. Temporal relationships between urinary salt retention and altered systemic hemodynamics in dogs with experimental cirrhosis
128. Renal sodium retention and ascites formation in dogs with experimental cirrhosis but without portal hypertension or increased splanchnic vascular capacity
129. Natural history and predictive factors of hepatorenal syndrome in cirrhosis with ascites
130. Studies of the cardiovascular system in the hypotension of liver failure
131. Renal and cardiovascular dysfunction in liver disease
132. Increased arterial compliance in decompensated cirrhosis
133. Nitric oxide synthase inhibition for one week improves renal sodium and water excretion in cirrhotic rats with ascites
134. Normalization of nitric oxide production corrects arterial vasodilation and hyperdynamic circulation in cirrhotic rats
135. Cirrhosis with ascites: Increased atrial natriuretic peptide messenger RNA expression in rat ventricle
136. Renal nerves mediate blunted natriuresis to atrial natriuretic peptide in cirrhotic rats
137. Reversal of atrial natriuretic peptide resistance by increasing distal tubular sodium delivery in patients with decompensated cirrhosis
138. Indomethacin-induced renal dysfunction in patients with well-compensated cirrhosis
139. Comparison of vascular nitric oxide production and systemic hemodynamics in cirrhosis versus prehepatic portal hypertension in rats
140. Endothelin-1 and endothelin-3 in cirrhosis: Relations to systemic and splanchnic haemodynamics
141. Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome
142. Role of vasopressin in abnormal water excretion in cirrhotic patients
143. Splanchnic and renal elimination and release of catecholamines in cirrhosis. Evidence of enhanced sympathetic nervous activity in patients with decompensated cirrhosis
144. Interrelationship between cardiac output and vascular resistance as determinants of effective arterial blood volume in cirrhotic patients
145. Vasopressin gene expression in rats with experimental cirrhosis
146. New classification with prognostic value in cirrhotic patients
147. Blockade of the hydroosmotic effect of vasopressin normalizes water excretion in cirrhotic rats
148. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis
149. Role of water channel AQP-CD in water retention in SIADH and cirrhotic rats
150. Increased gene expression of water channel in cirrhotic rat kidneys
151. Dysregulation of renal aquaporins and Na-Cl cotransporter in CC14-induced cirrhosis
152. Renal function abnormalities, prostaglandins, and effects of nonsteroidal anti-inflammatory drugs in cirrhosis with ascites. An overview with emphasis on pathogenesis
153. Complications of diuresis in the alcoholic patient with ascites: A controlled trial
154. Treatment of ascites in cirrhosis. Diuretics, peritoneovenous shunt, and large-volume paracentesis
155. Large volume paracentesis and intravenous dextran to treat tense ascites
156. Comparison of paracentesis and diuretics in the treatment of cirrhotics with tense ascites. Results of a randomized study
157. Randomized comparative study of therapeutic paracentesis with and without intravenous albumin in cirrhosis
158. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis
159. Diuretic requirements after therapeutic paracentesis in non-azotemic patients with cirrhosis. A randomized double-blind trial of spironolactone versus placebo
160. Peritoneovenous shunts - Devices of last resort
161. A comparison of paracentesis and transjugular intrahepatic portosystemic shunting in patients with ascites
162. Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt
163. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: Clinical, laboratory, psychometric, and electroencephalographic investigations
164. Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: Results of a prospective controlled study
165. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome
166. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients
167. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion
168. Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine